141 related articles for article (PubMed ID: 33046518)
1. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
Shi Y; Cai Q; Jiang Y; Huang G; Bi M; Wang B; Zhou Y; Wang G; Ying H; Tao Z; Shi C; Guo Q; Gao C
Clin Cancer Res; 2020 Dec; 26(24):6445-6452. PubMed ID: 33046518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi Y; Cui J; Zhou H; Zhang X; Zou L; Cao J; Gao Y; Jin C; Li X; Liu H; Peng Z; Xie L; Zhang H; Zhang W; Zhang H; Zhong L; Zhou F; Guo G; He W
Cancer Immunol Immunother; 2023 Sep; 72(9):2991-3002. PubMed ID: 37289256
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Shi Y; Wu J; Wang Z; Zhang L; Wang Z; Zhang M; Cen H; Peng Z; Li Y; Fan L; Guo Y; Ma L; Cui J; Gao Y; Yang H; Zhang H; Wang L; Zhang W; Zhang H; Xie L; Jiang M; Zhou H; Shuang Y; Su H; Ke X; Jin C; Du X; Du X; Liu L; Xi Y; Ge Z; Feng R; Zhang Y; Zhou S; Xie F; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):12. PubMed ID: 33436023
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
[TBL] [Abstract][Full Text] [Related]
5. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
[TBL] [Abstract][Full Text] [Related]
6. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
[TBL] [Abstract][Full Text] [Related]
7. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
12. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
[TBL] [Abstract][Full Text] [Related]
13. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
14. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
Bergsma EJ; Elgawly M; Mancuso D; Orr R; Vuskovich T; Seligson ND
Ann Pharmacother; 2024 Apr; 58(4):407-415. PubMed ID: 37466080
[TBL] [Abstract][Full Text] [Related]
18. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
19. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Judson I; Morden JP; Kilburn L; Leahy M; Benson C; Bhadri V; Campbell-Hewson Q; Cubedo R; Dangoor A; Fox L; Hennig I; Jarman K; Joubert W; Kernaghan S; López Pousa A; McNeil C; Seddon B; Snowdon C; Tattersall M; Toms C; Martinez Trufero J; Bliss JM
Lancet Oncol; 2019 Jul; 20(7):1023-1034. PubMed ID: 31160249
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
